Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines.

Trial Profile

Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2016

At a glance

  • Drugs Poliovirus vaccine inactivated (Primary)
  • Indications Poliomyelitis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 23 Mar 2010 Actual patient number (225) added as reported by ClinicalTrials.gov.
    • 23 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 23 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top